TDIQ software performs various analyses by Angle Corrected Displacement and Strain to measure myocardial viability. TSI (Tissue Strain Imaging) evaluates and clearly displays the regional myocardial strain quantitatively during systole. Tissue tracking and angle correction for radial information, performed with these advanced applications, expands the range of quantitative evaluations available. TSI, along with displacement imaging, also can be utilized for bi-ventricular pacing.

For more information about the Aplio CV, TAMS and its wide range of medical imaging products, please visit www.medical.toshiba.com.


About Toshiba
With headquarters in Tustin, Calif., Toshiba America Medical Systems markets, sells, distributes and services diagnostic imaging systems, and coordinates clinical diagnostic imaging research for all modalities in the United States. Toshiba Medical Systems Corporation, an independent group company of Toshiba Corporation, is a global leading provider of diagnostic medical imaging systems and comprehensive medical solutions, such as CT, X-ray, Ultrasound, Nuclear Medicine, MRI and information systems. Toshiba Corporation is a leader in information and communications systems, electronic components, consumer products, and power systems. Toshiba has approximately 161,000 employees worldwide and annual sales of $53 billion.

AplioTM is a trademark of Toshiba Medical Systems Corporation.

Back to HCB News

More Industry Headlines